Acne Vulgaris - Pipeline Review, H2 2014

Date: September 30, 2014
Pages: 147
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A1FF4E1E589EN
Leaflet:

Download PDF Leaflet

Acne Vulgaris - Pipeline Review, H2 2014
Summary

Global Markets Direct’s, ‘Acne Vulgaris - Pipeline Review, H2 2014’, provides an overview of the Acne Vulgaris’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acne Vulgaris Overview
Therapeutics Development
Pipeline Products for Acne Vulgaris - Overview
Pipeline Products for Acne Vulgaris - Comparative Analysis
Acne Vulgaris - Therapeutics under Development by Companies
Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes
Acne Vulgaris - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Acne Vulgaris - Products under Development by Companies
Acne Vulgaris - Products under Investigation by Universities/Institutes
Acne Vulgaris - Companies Involved in Therapeutics Development
Boehringer Ingelheim GmbH
Photocure ASA
Allergan, Inc.
Valeant Pharmaceuticals International, Inc.
GlaxoSmithKline plc
Galderma S.A.
Toyama Chemical Co., Ltd.
AntiCancer, Inc.
Cosmo Pharmaceuticals S.p.A
XOMA Corporation
Provectus Biopharmaceuticals, Inc.
Deltanoid Pharmaceuticals Inc.
Phosphagenics Limited
Foamix Ltd.
AndroScience Corporation
ELORAC, Inc.
Cutanea Life Sciences
Braintree Laboratories, Inc.
Maruho Co., Ltd.
RestorGenex Corporation
Ensoltek Co., Ltd.
Ausio Pharmaceuticals, LLC
XBiotech USA, Inc.
Advancell
Celtaxsys, Inc.
Delenex Therapeutics AG
Dermira Inc.
Kasiak Research Pvt. Ltd.
Biomar Microbial Technologies
Thesan Pharmaceuticals, Inc.
OrigImm e.U.
Acne Vulgaris - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(adapalene + benzoyl peroxide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ozenoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trifarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aczone X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASCJ-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
methyl aminolevulinate hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gevokizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-0301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DRM-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLI-1100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD2475/101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-10229570-AAA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RA-18C3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refaglo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
finasteride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-0601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-0604 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-1940029 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-10215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FX-125L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RES-440 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
becocalcidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTX-4430 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DLX-2323 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANs-29 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AD-037 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Acne and Related Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
salicylic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Acne and Inflammatory Skin Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DLX-2681 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipo-4MA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hesed-4000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Acne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Acne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Acne Vulgaris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acne Vulgaris - Recent Pipeline Updates
Acne Vulgaris - Dormant Projects
Acne Vulgaris - Discontinued Products
Acne Vulgaris - Product Development Milestones
Featured News & Press Releases
May 08, 2014: Novan Therapeutics' Positive Phase 2 Results Provide Foundation for SB204 as a Non-Antibiotic, First-in-Class Product to Treat Acne Vulgaris
Apr 23, 2014: Novan Therapeutics' Abstract Accepted for Poster Session at 2014 Society for Investigative Dermatology Annual Meeting
Apr 23, 2014: Phosphagenics Completes Enrolment in Phase 2 Acne Treatment Trial
Mar 19, 2014: Novan Announces Positive Phase 2 Results for Novel Acne Treatment
Jun 25, 2013: Xoma's Development Partner Servier Launches Proof-of-concept Clinical Program for Gevokizumab
Feb 28, 2013: Meda's Acnex Receives Registration Approval In Europe
Feb 28, 2013: Novan Therapeutics On Path To Develop First Topical Acne Treatment
Feb 19, 2013: Galderma's Epiduo Gel Obtains FDA Approval To Treat Acne In Children As Young As Nine Years Old
Jan 07, 2013: Xoma Announces Positive Interim Results From Gevokizumab Phase II Study For Moderate To Severe Acne Vulgaris
Dec 12, 2012: XBiotech Announces Positive Phase II Clinical Trial Results For MABp1 In Acne Vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES


Number of Products under Development for Acne Vulgaris, H2 2014
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Comparative Analysis by Unknown Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Acne Vulgaris - Pipeline by Boehringer Ingelheim GmbH, H2 2014
Acne Vulgaris - Pipeline by Photocure ASA, H2 2014
Acne Vulgaris - Pipeline by Allergan, Inc., H2 2014
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014
Acne Vulgaris - Pipeline by GlaxoSmithKline plc, H2 2014
Acne Vulgaris - Pipeline by Galderma S.A., H2 2014
Acne Vulgaris - Pipeline by Toyama Chemical Co., Ltd., H2 2014
Acne Vulgaris - Pipeline by AntiCancer, Inc., H2 2014
Acne Vulgaris - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014
Acne Vulgaris - Pipeline by XOMA Corporation, H2 2014
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014
Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2014
Acne Vulgaris - Pipeline by Phosphagenics Limited, H2 2014
Acne Vulgaris - Pipeline by Foamix Ltd., H2 2014
Acne Vulgaris - Pipeline by AndroScience Corporation, H2 2014
Acne Vulgaris - Pipeline by ELORAC, Inc., H2 2014
Acne Vulgaris - Pipeline by Cutanea Life Sciences, H2 2014
Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H2 2014
Acne Vulgaris - Pipeline by Maruho Co., Ltd., H2 2014
Acne Vulgaris - Pipeline by RestorGenex Corporation, H2 2014
Acne Vulgaris - Pipeline by Ensoltek Co., Ltd., H2 2014
Acne Vulgaris - Pipeline by Ausio Pharmaceuticals, LLC, H2 2014
Acne Vulgaris - Pipeline by XBiotech USA, Inc., H2 2014
Acne Vulgaris - Pipeline by Advancell, H2 2014
Acne Vulgaris - Pipeline by Celtaxsys, Inc., H2 2014
Acne Vulgaris - Pipeline by Delenex Therapeutics AG, H2 2014
Acne Vulgaris - Pipeline by Dermira Inc., H2 2014
Acne Vulgaris - Pipeline by Kasiak Research Pvt. Ltd., H2 2014
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2014
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H2 2014
Acne Vulgaris - Pipeline by OrigImm e.U., H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Acne Vulgaris Therapeutics - Recent Pipeline Updates, H2 2014
Acne Vulgaris - Dormant Projects, H2 2014
Acne Vulgaris - Discontinued Products, H2 2014

LIST OF FIGURES


Number of Products under Development for Acne Vulgaris, H2 2014
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014
Acne Vulgaris - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 54 pages
Pemphigus Vulgaris - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 25 pages
Pemphigus Vulgaris - Pipeline Review, Q2 2011 US$ 500.00 Apr, 2011 · 43 pages
Pemphigus Vulgaris – Pipeline Review, H2 2012 US$ 2,000.00 Dec, 2012 · 32 pages
Acne Vulgaris Global Clinical Trials Review, Q4, 2010 US$ 1,000.00 Dec, 2010 · 67 pages

Ask Your Question

Acne Vulgaris - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: